Results 1 to 10 of about 2,046,127 (279)

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND CALCIUM CHANNEL BLOCKERS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSOCIATED WITH STABLE ANGINA AND ARTERIAL HYPERTENSION

open access: yesŽurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, 2020
The review considers approaches to selecting an antihypertensive drug from the group of angiotensin-converting enzyme inhibitors and calcium channel blockers in patients with chronic obstructive pulmonary disease associated with stable angina and ...
Paplauskaya E. E.
doaj   +1 more source

A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE

open access: yesРациональная фармакотерапия в кардиологии, 2015
Translation articles: G. Savarese, P. Costanzo, J.G.F. Cleland, E. Vassallo, D. Ruggiero, G. Rosano, P. Perrone-Filardi «A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without ...
G. Savarese   +6 more
doaj   +3 more sources

ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN ACUTE MYOCARDIAL INFARCTION: WHEN TO START THERAPY AND WHICH DRUG TO USE?

open access: yesРациональная фармакотерапия в кардиологии, 2015
Data of studies devoted to application of angiotensin converting enzyme (ACE) inhibitors in acute myocardial infarction are reviewed. The reasons of ambiguous results are discussed.
S. Y. Martsevich, S. N. Tolpygina
doaj   +3 more sources

Delayed angioedema during therapy with angiotensin-converting enzyme inhibitors [PDF]

open access: yesVojnosanitetski Pregled, 2011
Introduction. Angiotensin-converting enzyme inhibitors are leading cause of drug-induced angioedema, with incidence of 0.1 to 0.2%. The angioedema is not of immune nature; in predisposed individuals it is caused by accumulation of vasoactive mediators
Janković Slobodan M.   +1 more
doaj   +1 more source

Why not change the therapy of hypertension in patients with COVID-19. Dual role of angiotensin-converting enzyme 2

open access: yesArterial Hypertension, 2022
Despite many organizational and medical efforts, the COVID-19 epidemic continues and is taking a lethal toll. Preliminary reports have already reported that the mortality associated with this disease is much higher in people with comorbidities, including
Jerzy Głuszek, Teresa Kosicka
doaj   +1 more source

Angiotensin-Converting Enzyme Inhibitors and Angioedema [PDF]

open access: yesAllergy, Asthma and Immunology Research, 2010
To investigate the incidence and clinical characteristics of angioedema associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) in an outpatient allergy department.A retrospective review of medical records of new patients seen in an allergy clinic.
Sánchez-Borges, Mario   +1 more
openaire   +2 more sources

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Evidence From Randomized Controlled Trials (RCTs) of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II–Receptor Blockers — Questions Remain Unsolved

open access: yesJournal of Pharmacological Sciences, 2010
Recent randomized controlled trials showed that blockade of the renin–angiotensin system (RAS) by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II–receptor blockers (ARBs) reduced cardiovascular and renal events.
Shinichiro Ueda
doaj   +1 more source

New Drugs: Angiotensin converting enzyme inhibitors [PDF]

open access: yesBMJ, 1988
The development of angiotensin converting enzyme inhibitors is often cited as a prime example of task oriented research. The truth is far from this, and, as so often, chance played a large part in the development of this group of drugs. Some 25 years ago a group of Brazilian pharmacologists was searching for substances that would block the inactivation
openaire   +2 more sources

Effect of ACE Inhibitors, ARBs, and Other Antihypertensive Drugs on Hypertensive Patients with COVID-19 Infection

open access: yesNovelty in Biomedicine
Background: To investigate differences in disease severity and outcomes among COVID-19 patients with a history of hypertension using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive drugs.
Seyedpouzhia Shojaei   +7 more
doaj   +1 more source

RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION

open access: yesРациональная фармакотерапия в кардиологии, 2015
Angiotensin converting enzyme inhibitors are the first line medicine for the treatment of the most of cardiovascular diseases. There is no class-effect for these drugs in myocardial infarction therapy.
I. V. Szirov, E. V. Malichenko
doaj   +3 more sources

Home - About - Disclaimer - Privacy